AP NEWS

Chronic Obstructive Pulmonary Disease (COPD) Drugs: Worldwide Markets, 2019-2023 - Strong Pipeline and New Drug Approvals; Driving Growth - ResearchAndMarkets.com

February 7, 2019

DUBLIN--(BUSINESS WIRE)--Feb 7, 2019--The “Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

The chronic obstructive pulmonary disease (COPD) drugs market will register a CAGR of almost 4% by 2023.

There are several lifestyle-related factors such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD.

In addition to tobacco smoke, there are other factors such as occupational exposure, outdoor pollution, exposure to second-hand or passive smoking, smoke from the burning of biomass, respiratory infections, poor nutritional status, chronic asthma, impaired lung growth, poor socio-economic status and dietary factors, which lead directly or indirectly to COPD.

Apart from lifestyle factors, there are factors such as old age and presence of rare genetic disorders, which contribute to the rising prevalence of COPD.

Strong pipeline and new drug approvals

The pipeline for the treatment of COPD includes several drug combinations, which can provide a wide range of therapeutic benefits.

These drug combinations are presently in the late stages of development, with some expected to be launched in the market during the forecast period. These molecules combine the properties of drugs from different classes and have diversified therapeutic mechanisms of action and hence are expected to change the course of COPD treatment.

Low diagnosis rates for COPD

There is a lack of knowledge and awareness about COPD especially in the developing countries due to which primary care practitioners (PCPs) and other healthcare providers delay or incorrectly diagnose COPD.

Another major factor contributing to the poor diagnosis of COPD is the diagnostic confusion between COPD and asthma. Thus, poor or incorrect diagnosis is a major challenge as it prevents people with COPD from getting a proper diagnosis which, in turn, has a negative impact on market growth.

Competitive Landscape

The chronic obstructive pulmonary disease (COPD) drugs market appears to be moderately concentrated and with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

Key Players

AstraZeneca Boehringer Ingelheim GlaxoSmithKline Novartis Teva Pharmaceutical

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

Market definition Market sizing 2018 Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

Comparison by product Combination therapy - Market size and forecast 2018-2023 Monotherapy - Market size and forecast 2018-2023 Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE

Chronic bronchitis Emphysema

PART 10: GEOGRAPHIC LANDSCAPE

Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity

PART 11: DRIVERS AND CHALLENGES

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

Overview Landscape disruption

PART 14: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors AstraZeneca Boehringer Ingelheim GlaxoSmithKline Novartis Teva Pharmaceutical

For more information about this report visit https://www.researchandmarkets.com/research/5d4snr/chronic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190207005534/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/07/2019 09:48 AM/DISC: 02/07/2019 09:48 AM

http://www.businesswire.com/news/home/20190207005534/en

AP RADIO
Update hourly